A heterocyclic compound represented by Chemical Formula 1 and an organic light emitting device including the same, and the heterocyclic compound which is used as a material of an organic material layer of the organic light emitting device and provides improved efficiency, low driving voltage and improved lifetime characteristics of the organic light emitting device.

##STR00001##

A heterocyclic compound represented by Chemical Formula 1 and an organic light emitting device including the same, and the heterocyclic compound which is used as a material of an organic material layer of the organic light emitting device and provides improved efficiency, low driving voltage and improved lifetime characteristics of the organic light emitting device.

##STR00001##

The present invention relates to a novel anthracene derivative, for an organic light-emitting device, and an organic light-emitting device comprising same, the anthracene derivative enabling excellent device characteristics when used as a light-emitting material.

The present invention relates to a novel anthracene derivative, for an organic light-emitting device, and an organic light-emitting device comprising same, the anthracene derivative enabling excellent device characteristics when used as a light-emitting material.

The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine-based inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.

The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine-based inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.

The present disclosure provides a compound represented by structural formula (I-0):

##STR00001##

or a pharmaceutically acceptable salt thereof useful for treating a cancer.

The present disclosure provides a compound represented by structural formula (I-0):

##STR00001##

or a pharmaceutically acceptable salt thereof useful for treating a cancer.

The invention relates to new proline derivatives of formula (I) as cGAS inhibitors,

##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compounds for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).

Disclosed are a series of photoisomeric compounds, preparation method therefor and device comprising the compounds, wherein a photoisomeric compound-graphene molecular junction device is formed by linking the photoisomeric compound to a gap of two-dimensional monolayer graphene having a nano-gap array via an amide covalent bond. When a single photoisomeric compound is bridged to the gap of the two-dimensional monolayer graphene having a nano-gap array, the devices have a reversible light-controlled switching function and a reversible electrically-controlled switching function. A molecular switch device prepared by the method can achieve a high reversibility and a good reproducibility. The number of light-controlled switching cycles can exceed 10.sup.4, and the number of electrically-controlled switching cycles can reach about 10.sup.5 or greater. Moreover, the above-mentioned reversible molecular switch device remains stable within a period of more than one year. In addition, flexible non-losable organic memory transistor devices and light-responsive organic transistor devices can be constructed using the above-mentioned series of photoisomeric compounds.